| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Imatinib Impurity E is an impurity of imatinib. The parent drug imatinib is an orally bioavailable tyrosine kinase inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR, and c-kit kinase activity. Imatinib binds near the ATP binding site, stabilizing a closed conformation and reducing enzyme activity. The impurity may share some structural features but is not intended for therapeutic use.
|
|---|---|
| ln Vitro |
As a pharmaceutical impurity, Imatinib Impurity E is not tested for standalone in vitro pharmacological activity. Imatinib, its parent drug, potently inhibits the proliferation of BCR-ABL-expressing cells with IC50 values in the low nanomolar range. The impurity is used as a control and standard in analytical chemistry to ensure drug purity, as impurities could potentially affect safety or efficacy if present above acceptable limits.
|
| ln Vivo |
No independent in vivo studies are reported for Imatinib Impurity E as a therapeutic agent. Imatinib is clinically effective in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The impurity is not administered for pharmacological effect but is monitored in quality control to ensure that impurity levels are within ICH guidelines for safe human consumption.
|
| Enzyme Assay |
Imatinib Impurity E is used in non-cellular analytical method development. The compound is dissolved in an organic solvent such as DMSO or methanol to prepare a stock solution (e.g., 1 mg/mL). It is then diluted to working concentrations for HPLC or LC-MS analysis to establish a calibration curve. The standard is injected into the chromatographic system, and parameters such as retention time, peak area, and resolution are recorded to validate the method.
|
| Cell Assay |
For cell-based studies, Imatinib Impurity E is not used as an independent treatment. It serves as an analytical standard for quantifying this impurity in cell culture samples from cells exposed to imatinib. After sample collection and protein precipitation, the impurity standard is spiked into the samples at a fixed concentration. Samples are analyzed by LC-MS/MS to determine if any metabolic conversion of imatinib to this impurity occurs in cellular systems.
|
| Animal Protocol |
For in vivo studies, Imatinib Impurity E is not administered to animals. It is used as an analytical standard for quantifying the impurity in plasma or tissue samples from animals dosed with imatinib. After sample collection, the impurity standard is spiked into the samples at a known concentration. Following extraction and LC-MS/MS analysis, the concentration of the impurity is determined to support ADME and toxicology studies of imatinib.
|
| ADME/Pharmacokinetics |
As an impurity standard, Imatinib Impurity E has no independent pharmacokinetic parameters. Imatinib is well absorbed after oral administration with a bioavailability of 98%, has high plasma protein binding (∼95%), and an elimination half-life of approximately 18 hours. The impurity, if formed, would be expected at very low levels relative to the parent drug and would likely follow similar elimination pathways if systemically absorbed.
|
| Toxicity/Toxicokinetics |
Imatinib Impurity E is handled as a reference standard in analytical laboratories. No specific toxicity data is available for this impurity. Imatinib has a well-characterized safety profile including edema, nausea, rash, and fatigue. Impurity levels in drug products are controlled to ensure safety. Standard laboratory precautions for handling organic compounds (gloves, safety glasses, fume hood) are recommended. Not intended for human consumption.
|
| References |
[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.
[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [3]. Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. [4]. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8. [5]. Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630. |
| Additional Infomation |
Imatinib Impurity E is not a drug but a characterized impurity and analytical standard. It has no approved therapeutic status and is not intended for human use. This compound is used for analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of imatinib. The product can be used as reference standards and further traceability against pharmacopeial standards can be provided. Imatinib is an approved drug for CML, ALL, and GIST.
|
| Molecular Formula |
C52H48N12O2
|
|---|---|
| Molecular Weight |
873.02
|
| Exact Mass |
872.402
|
| CAS # |
1365802-18-1
|
| PubChem CID |
71315751
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
9.484
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
66
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC4=CC=C(C=C4)C(=O)NC5=CC(=C(C)C=C5)NC6=NC=CC(=N6)C7=CN=CC=C7)NC8=NC=CC(=N8)C9=CN=CC=C9
|
| InChi Key |
DZHKYOWYCVBDPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C52H48N12O2/c1-35-7-17-43(29-47(35)61-51-55-23-19-45(59-51)41-5-3-21-53-31-41)57-49(65)39-13-9-37(10-14-39)33-63-25-27-64(28-26-63)34-38-11-15-40(16-12-38)50(66)58-44-18-8-36(2)48(30-44)62-52-56-24-20-46(60-52)42-6-4-22-54-32-42/h3-24,29-32H,25-28,33-34H2,1-2H3,(H,57,65)(H,58,66)(H,55,59,61)(H,56,60,62)
|
| Chemical Name |
N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[[4-[[4-[[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]carbamoyl]phenyl]methyl]piperazin-1-yl]methyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1454 mL | 5.7272 mL | 11.4545 mL | |
| 5 mM | 0.2291 mL | 1.1454 mL | 2.2909 mL | |
| 10 mM | 0.1145 mL | 0.5727 mL | 1.1454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
